Flamel Technologies S.A. (ADR) (FLML) Releases Earnings Results, Misses Expectations By $-0.08 EPS

Flamel Technologies S.A. (ADR) (FLML) reported quarterly earnings results on Monday, May-9-2016. The company reported $0.04 earnings per share for the quarter, missing the analyst consensus estimate by $-0.08. Analysts had a consensus of $0.12. The company posted revenue of $36.20 million in the period, compared to analysts expectations of $32.52 million. The company’s revenue was up 10.7% compared to the same quarter last year.

Flamel Technologies S.A. (ADR) closed down -0.51 points or -4.49% at $10.86 with 2,28,511 shares getting traded on Friday. Post opening the session at $11.14, the shares hit an intraday low of $10.64 and an intraday high of $11.24 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.

In a different news, on Mar 22, 2016, Phillandas T. Thompson (officer ) purchased 10,000 shares at $11.10 per share price. According to the SEC, on Mar 21, 2016, Michael S Anderson (CEO) purchased 5,000 shares at $11.04 per share price. On Mar 21, 2016, Sandra L Hatten (Sr. VP, Quality & Reg Affairs) purchased 3,000 shares at $11.01 per share price, according to the Form-4 filing with the securities and exchange commission.

Flamel Technologies SA is a pharmaceutical company. The Company’s focus is on the development of safer and more efficacious formulations and other medical needs in the process. Micropump platform applied to sodium oxybate in a First-in-Man (FIM) clinical study in healthy volunteers. The Company’s products include Bloxiverz and Coreg CR. Bloxiverz (Neostigmine Methylsulfate Injection) is a drug used intravenously in the operating room for the reversal of the effects of non-depolarizing neuromuscular blocking agents after surgery. Coreg CR the lead product using the Company’s Micropump drug delivery platform. Coreg CR is an extended-release formulation of Coreg (carvedilol phosphate) a non-selective antagonist of Beta 1 Beta 2 adrenergic receptors and a selective antagonist of Alpha 1 adrenergic receptors.

Flamel Technologies S.A. (ADR)

Leave a Reply

Flamel Technologies S.A. (ADR) - Is it time to Sell?

Top Brokerage Firms are advising their investors on Flamel Technologies S.A. (ADR). Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.